SMMHC Polyclonal Antibody for IF, IHC, WB, ELISA
Cat no : 21404-1-AP
MYH11, Myosin 11, Myosin heavy chain 11, SMHC, SMMHC, SMM-HC, smooth muscle myosin heavy chain
Validation Data Gallery
|Positive WB detected in||mouse uterus tissue, mouse colon tissue|
|Positive IHC detected in||human colon tissue, human skeletal muscle tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||mouse heart tissue|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
The 21404-1-AP immunogen is Fusion Protein SMMHC protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||SMMHC fusion protein Ag16114|
|Full Name||myosin, heavy chain 11, smooth muscle|
|Calculated molecular weight||1979aa,228 kDa|
|Observed molecular weight||200 kDa|
|GenBank accession number||BC104906|
|Gene ID (NCBI)||4629|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
SMMHC (smooth muscle myosin heavy chain; MYH11) is a contractile protein of smooth muscle cells. It is specifically expressed in cells derived from smooth muscle lineages. SMMHC is used as vascular smooth muscle cell (vSMC) contractile marker. It is also an excellent marker for myoepithelial cells, with no or few cross-reaction with myofibroblasts, thus very useful in the evaluation of stromal invasion.
Exp Cell Res
Autophagy is involved in the differentiation of epicardial progenitor cells into vascular smooth muscle cells in mice.
Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.
Am J Physiol Renal Physiol
Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction.
CTRP13 attenuates vascular calcification by regulating Runx2.
Regulated lysosomal exocytosis mediates cancer progression.
Nesfatin-1 promotes VSMC migration and neointimal hyperplasia by upregulating matrix metalloproteinases and downregulating PPARγ.